AtriCure (NASDAQ:ATRC) Downgraded to “Hold” Rating by Zacks Research

AtriCure (NASDAQ:ATRC) was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

Other equities research analysts have also issued research reports about the stock. UBS Group decreased their price objective on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Raymond James Financial set a $52.00 target price on AtriCure in a research report on Tuesday, July 21st. Wall Street Zen downgraded shares of AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Citigroup reiterated a “market outperform” rating on shares of AtriCure in a research note on Tuesday, July 21st. Finally, Canaccord Genuity Group lifted their price objective on AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $48.62.

AtriCure Trading Down 1.2%

Shares of AtriCure stock opened at $48.68 on Monday. The company has a market capitalization of $2.48 billion, a P/E ratio of 231.82 and a beta of 1.20. The stock has a fifty day simple moving average of $36.67 and a 200 day simple moving average of $31.97. AtriCure has a 12-month low of $25.36 and a 12-month high of $49.88. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The business had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same period last year, the business earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, sell-side analysts anticipate that AtriCure will post 0.2 earnings per share for the current fiscal year.

Insider Buying and Selling at AtriCure

In related news, insider Justin J. Noznesky sold 6,182 shares of AtriCure stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $38.80, for a total transaction of $239,861.60. Following the completion of the sale, the insider owned 100,219 shares of the company’s stock, valued at approximately $3,888,497.20. This trade represents a 5.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Vinayak Doraiswamy sold 6,000 shares of the company’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $38.88, for a total value of $233,280.00. Following the completion of the transaction, the insider owned 86,511 shares in the company, valued at $3,363,547.68. This represents a 6.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 44,246 shares of company stock worth $1,691,895 in the last ninety days. Insiders own 4.00% of the company’s stock.

Institutional Trading of AtriCure

Several institutional investors and hedge funds have recently made changes to their positions in ATRC. Geneos Wealth Management Inc. bought a new position in AtriCure in the second quarter valued at $37,000. Harbor Investment Advisory LLC purchased a new position in shares of AtriCure during the 2nd quarter valued at about $40,000. Allworth Financial LP purchased a new stake in AtriCure in the second quarter worth approximately $43,000. Smartleaf Asset Management LLC grew its position in AtriCure by 59.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after acquiring an additional 429 shares during the last quarter. Finally, Fifth Third Bancorp bought a new stake in shares of AtriCure in the 1st quarter worth approximately $51,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.